CCCC [NASD]
C4 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.19 Insider Own0.50% Shs Outstand48.92M Perf Week-16.84%
Market Cap467.36M Forward P/E- EPS next Y-2.94 Insider Trans0.00% Shs Float43.45M Perf Month-16.14%
Income-106.60M PEG- EPS next Q-0.74 Inst Own82.30% Short Float / Ratio9.09% / 8.15 Perf Quarter-21.72%
Sales48.30M P/S9.68 EPS this Y-18.30% Inst Trans-1.77% Short Interest3.95M Perf Half Y10.19%
Book/sh6.50 P/B1.23 EPS next Y-14.40% ROA-21.60% Target Price23.31 Perf Year-77.75%
Cash/sh5.37 P/C1.49 EPS next 5Y- ROE-30.10% 52W Range4.84 - 38.05 Perf YTD-75.16%
Dividend- P/FCF- EPS past 5Y- ROI-20.50% 52W High-78.48% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low69.21% ATR0.82
Employees121 Current Ratio7.20 Sales Q/Q-20.00% Oper. Margin- RSI (14)42.31 Volatility13.77% 10.05%
OptionableYes Debt/Eq0.04 EPS Q/Q-28.30% Profit Margin- Rel Volume0.64 Prev Close8.00
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume484.31K Price8.19
Recom2.50 SMA20-9.49% SMA50-7.19% SMA200-29.74% Volume36,751 Change2.37%
Nov-04-22Downgrade JP Morgan Overweight → Neutral $22 → $15
Oct-11-22Initiated Morgan Stanley Underweight $6
Apr-28-22Initiated Credit Suisse Underperform $10
Apr-11-22Downgrade BofA Securities Buy → Neutral $46 → $15
Mar-10-22Initiated JP Morgan Overweight $43
Feb-11-22Resumed BMO Capital Markets Outperform $57
Feb-10-22Initiated Wells Fargo Equal Weight $25
Nov-23-21Initiated BofA Securities Buy $54
Oct-14-21Initiated SVB Leerink Mkt Perform $20
Sep-30-21Initiated Stifel Hold $45
Show Previous Ratings
Nov-13-22 07:13AM
Nov-08-22 09:55AM
Nov-03-22 08:25AM
07:00AM
Nov-02-22 10:01AM
09:02AM Loading…
Oct-03-22 09:02AM
Sep-29-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 08:22AM
Aug-10-22 06:05AM
Aug-07-22 08:21AM
Aug-04-22 09:15AM
08:00AM
Aug-02-22 08:00AM
May-16-22 08:00AM
09:15AM Loading…
May-05-22 09:15AM
08:00AM
Apr-08-22 02:15PM
01:00PM
10:05AM
Mar-17-22 11:44AM
Mar-16-22 04:05PM
Mar-09-22 08:00AM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-07-22 04:45AM
Jan-12-22 11:09AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-29-21 12:00PM
08:00AM Loading…
Dec-17-21 08:00AM
Dec-01-21 07:28AM
Nov-22-21 12:00PM
Nov-10-21 04:01PM
08:34AM
Oct-26-21 10:41AM
Oct-09-21 09:14AM
Sep-17-21 10:27AM
Aug-11-21 04:02PM
04:01PM
Aug-10-21 01:31AM
Jul-21-21 04:24AM
Jul-19-21 01:44PM
Jun-21-21 04:01PM
08:00AM
Jun-16-21 07:51PM
Jun-14-21 04:12PM
08:00AM
Jun-07-21 07:00AM
May-26-21 07:00AM
May-20-21 04:01PM
May-13-21 04:01PM
May-12-21 07:00AM
May-02-21 03:53AM
Apr-10-21 03:05PM
Mar-10-21 04:41PM
Mar-02-21 11:50PM
Feb-24-21 07:00AM
Feb-11-21 07:00AM
Jan-19-21 07:00AM
Jan-07-21 07:00AM
Jan-06-21 07:00AM
Dec-17-20 07:00AM
Nov-25-20 07:00AM
Nov-13-20 07:00AM
Nov-12-20 04:05PM
Oct-23-20 05:54PM
Oct-14-20 07:30AM
Oct-06-20 04:05PM
Oct-02-20 05:53PM
11:23AM
Oct-01-20 09:58PM
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Kenneth CarlDirectorOct 03Option Exercise3.907122,77991,698Oct 04 06:05 PM
Anderson Kenneth CarlDirectorJul 15Option Exercise3.901,4245,55690,986Jul 18 05:18 PM
Fisher StewartChief Scientific OfficerApr 12Option Exercise4.8828,084137,12071,390Apr 12 08:41 PM
Hirsch AndrewPresident & CEOApr 12Buy8.4010,00084,00010,000Apr 12 04:05 PM
Anderson Kenneth CarlDirectorJan 26Option Exercise3.902,1378,33887,975Jan 26 05:26 PM
Crystal AdamChief Medical OfficerJan 04Option Exercise6.4915,00097,35030,000Jan 05 04:30 PM
Crystal AdamChief Medical OfficerJan 04Sale31.6615,000474,96815,000Jan 05 04:30 PM
Crystal AdamChief Medical OfficerDec 22Option Exercise6.495,00032,45015,000Dec 23 04:10 PM
Salter MalcolmDirectorDec 17Sale30.2575522,83910,952Dec 17 04:28 PM
Fisher StewartChief Scientific OfficerDec 08Option Exercise3.5520,56273,00043,306Dec 10 04:30 PM